Journal of Chinese Integrative Medicine ›› 2010, Vol. 8 ›› Issue (3): 275-279.doi: 10.3736/jcim20100313
• Original Experimental Research • Previous Articles Next Articles
Jin Jina, Yang Zhanga, Wen-xiang Hub, Zheng-yao Zhanga, Nan-nan Xub, Qiu-li Zhoua
| [1] | Jin D, Lu FE, Chen G, Sun H, Lu XH . Effects of Huanglian Jiedu Decoction on phosphatidylinositol-3-kinase expression in target tissues of type 2 diabetic rats[J]. J Chin Integr Med, 2007,5(5):541-545 |
| 金丹, 陆付耳, 陈广, 孙焕, 陆小红 . 黄连解毒汤对2型糖尿病大鼠靶组织磷脂酰肌醇3激酶的影响[J]. 中西医结合学报, 2007,5(5):541-545 | |
| [2] | Leng SH, Lu FE, Tu QN, Xu LJ, Yang MW, Wang KF . Effects of Huanglian Jiedu Decoction on blood glucose and lipids metabolisms in type 2 diabetic rats[J]. Zhongguo Zhong Yi Ji Chu Yi Xue Za Zhi, 2003,9(4):4388-4389 |
| 冷三华, 陆付耳, 屠庆年, 徐丽君, 杨明炜, 王开富 . 黄连解毒汤对2型糖尿病大鼠血糖和血脂代谢的影响[J]. 中国中医基础医学杂志, 2003,9(4):4388-4389 | |
| [3] | Ding LB, Lu FE, Ye AL, Xu LJ, Wang KF . Effects of Huanglian Jiedu Decoction on leptin and resistin in insulin resistive rats[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2006,26(3):232-235 |
| 丁来标, 陆付耳, 叶爱丽, 徐丽君, 王开富 . 黄连解毒汤对胰岛素抵抗大鼠瘦素和抵抗素的影响[J]. 中国中西医结合杂志, 2006,26(3):232-235 | |
| [4] |
Chira EC, McMillen TS, Wang S, Haw A 3rd, O’Brien KD, Wight TN, Chait A .Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice[J]. Atherosclerosis, 2007,195(1):100-109
doi: 10.1016/j.atherosclerosis.2006.12.012 |
| [5] | Chen KX . Comprehension on treatment based on typing of hyperlipidemia[J]. Shi Zhen Guo Yi Guo Yao, 2002,12(13):750-751 |
| 陈康新 . 高脂血症的分型论治体会[J]. 时珍国医国药, 2002,12(13):750-751 | |
| [6] |
Zhang Y, Xie ML, Zhu LJ, Gu ZL . Therapeutic effect of osthole on hyperlipidemic fatty liver in rats[J]. Acta Pharmacol Sin, 2007,28(3):398-403
doi: 10.1111/aphs.2007.28.issue-3 |
| [7] |
Stulnig TM, Klocker H, Harwood HJ Jr, Jürgens G, Schönitzer D, Jarosch E, Huber LA, Amberger A, Wick G .In vivo LDL receptor and HMG-CoA reductase regulation in human lymphocytes and its alterations during aging[J]. Arterioscler Thromb Vasc Biol, 1995,15(7):872-878
doi: 10.1161/01.ATV.15.7.872 |
| [8] |
Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD . Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins[J]. Nat Med, 2004,10(12):1344-1351
doi: 10.1038/nm1135 |
| [9] |
Hammarstedt A, Andersson CX, Rotter Sopasakis V, Smith U . The effect of PPARgamma ligands on the adipose tissue in insulin resistance[J]. Prostaglandins Leukot Essent Fatty Acids, 2005,73(1):65-75
doi: 10.1016/j.plefa.2005.04.008 |
| [10] |
Huang C, Zhang Y, Gong Z, Sheng X, Li Z, Zhang W, Qin Y . Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway[J]. Biochem Biophys Res Commun, 2006,348(2):571-578
doi: 10.1016/j.bbrc.2006.07.095 |